UB
KAPA

UMB Bank’s Kairos Pharma KAPA Stock Holding History

UMB Bank’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-371,115
Closed -$564K – 2180
2024
Q4 		$564K Buy
+371,115
New +$569K 0.01% 394

Other funds holding KAPA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UMB Bank's KAPA Position: Q1 2025 in Review

UMB Bank sold out of Kairos Pharma (KAPA) in Q1 2025, closing a stake of 371,115 shares — an estimated $564K sold.

UMB Bank first reported a position in KAPA in Q4 2024 and held it in 1 quarter. The position peaked at $564K in Q4 2024. 8 funds tracked by Wall St. Rank hold KAPA as of Q1 2025.

  • UMB Bank reported no remaining Kairos Pharma position as of Q1 2025 after selling out during the quarter.
  • UMB Bank sold 371,115 Kairos Pharma shares in Q1 2025, an estimated $564K.
  • UMB Bank first reported a position in Kairos Pharma in Q4 2024 and held it in 1 quarter.
  • UMB Bank's Kairos Pharma position peaked at $564K in Q4 2024.
  • 8 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2025.

Based on UMB Bank's 13F filing for Q1 2025, filed 14 Apr 2025.